One Week Post Living‑Donor Nephrectomy Laboratory Interpretation
Your laboratory results at one week post‑nephrectomy are reassuring overall, showing expected physiologic adaptation with mild elevation in creatinine (1.11 mg/dL) and eGFR of 61 mL/min/1.73 m², which represents normal compensatory response to unilateral nephrectomy. The mildly elevated absolute neutrophil count (7.42 K/uL) and ALT (68 U/L) are common postoperative findings that warrant monitoring but typically resolve spontaneously.
Renal Function Assessment
Expected Immediate Post‑Nephrectomy Changes:
Your creatinine of 1.11 mg/dL (slightly above the 0.51–0.95 mg/dL reference range) and eGFR of 61 mL/min/1.73 m² represent the anticipated immediate decline in renal function following donor nephrectomy 1, 2.
Studies demonstrate that donors experience an initial 37–39% decline in renal function within the first week, which then stabilizes over subsequent months 3, 4.
Compensatory hyperfiltration begins immediately: The remaining kidney increases effective renal plasma flow by approximately 32.5% within the first week, with male donors showing greater compensatory response (46.9%) compared to female donors (26.7%) 1.
Your eGFR trajectory will likely show improvement over the next 6 weeks to 2 years, with an average increase of +1.06 mL/min/1.73 m² per year during this early compensatory phase 2.
Critical Point: Renal function typically stabilizes at 19–24% below baseline by 12 months post‑donation, representing permanent but acceptable reduction 3, 4.
Hematologic Findings
Mild Leukocytosis with Neutrophilia:
Your WBC of 11 K/uL (upper limit of normal) with absolute neutrophil count of 7.42 K/uL (above the 1.70–6.70 K/uL range) is consistent with normal postoperative inflammatory response 5.
This mild elevation at one week post‑surgery does not suggest infection in the absence of fever, wound complications, or other clinical signs 5.
No intervention required unless accompanied by clinical symptoms of infection or progressive elevation on repeat testing.
Hemoglobin and Hematocrit:
- Your hemoglobin of 12.7 g/dL and hematocrit of 37.8% are within normal limits, indicating no significant perioperative blood loss requiring intervention 6.
Liver Enzymes
Isolated ALT Elevation:
Your ALT of 68 U/L (above the 10–35 U/L range) with normal AST (31 U/L), alkaline phosphatase (64 U/L), and bilirubin (0.2 mg/dL) represents a common postoperative finding 7.
This isolated transaminase elevation likely reflects:
- Anesthetic agents or perioperative medications
- Transient hepatic congestion from surgical positioning
- Calcineurin inhibitor effects if you received any immunosuppressive prophylaxis (though unlikely in living donors) 7
Recheck ALT in 2–4 weeks: Values should normalize spontaneously without intervention in the absence of viral hepatitis, medication toxicity, or other hepatobiliary pathology 7.
Electrolytes and Metabolic Panel
All Within Normal Limits:
Sodium (137 mmol/L), potassium (4.2 mmol/L), chloride (101 mmol/L), bicarbonate (27 mmol/L), glucose (94 mg/dL), calcium (9 mg/dL), and BUN (19 mg/dL) are all reassuring 6.
Normal electrolytes indicate adequate hydration and no immediate metabolic derangements from reduced renal mass 6.
Recommended Follow‑Up Care
Immediate Monitoring (First 3 Months):
Measure serum creatinine and eGFR: Weekly for the first month, then every 2 weeks for months 2–3 6.
Blood pressure monitoring: Check at each visit, as hypertension prevalence increases from 9.3% pre‑donation to 22.1% post‑donation in long‑term follow‑up 3.
Urinalysis with urine protein quantification: Obtain baseline within the first month to establish post‑donation proteinuria status 6.
Repeat CBC and comprehensive metabolic panel: At 2–4 weeks to confirm resolution of neutrophilia and ALT elevation 6.
Baseline Imaging:
Abdominal ultrasound or CT scan: Obtain within 3–12 months post‑nephrectomy to assess the remaining kidney for compensatory hypertrophy, exclude hydronephrosis, and evaluate for perinephric collections 8, 9.
Ultrasound is preferred as first‑line imaging due to lack of radiation exposure and no need for nephrotoxic contrast 9.
Long‑Term Surveillance (Beyond 3 Months):
Serum creatinine and eGFR: Every 2–3 months during the first year, then every 6 months thereafter 6.
Annual urinalysis: Screen for proteinuria and hematuria, as new‑onset proteinuria warrants nephrology referral 6.
Blood pressure monitoring: At every clinical encounter, with aggressive treatment of hypertension to target <130/80 mmHg to minimize further renal injury 7, 3.
Metabolic screening: Monitor for diabetes, dyslipidemia, and calcium homeostasis derangements, which occur with increased frequency in living donors compared to matched healthy controls 10.
Red Flags Requiring Urgent Evaluation
Contact your transplant center immediately if you develop:
Persistent or worsening renal function: Creatinine rising above 1.5 mg/dL or eGFR declining below 50 mL/min/1.73 m² 6.
New‑onset proteinuria: Urine protein >300 mg/24 hours or protein‑to‑creatinine ratio >0.3 g/g 6.
Uncontrolled hypertension: Blood pressure consistently >140/90 mmHg despite lifestyle modifications 3.
Fever, flank pain, or wound complications: May indicate infection, hematoma, or other surgical complications requiring imaging and possible intervention 9.
Oliguria or anuria: Urine output <400 mL/24 hours suggests obstruction or vascular compromise requiring urgent ultrasound evaluation 6.
Prognosis and Long‑Term Outcomes
Reassuring Long‑Term Data:
Living kidney donors have comparable or lower mortality, ESRD risk, and cardiovascular disease compared to the general population when matched for baseline health 10.
Five‑year kidney function remains stable in most donors, with eGFR plateauing around 5 years post‑donation after initial compensatory hyperfiltration 2.
Donors with higher pre‑donation eGFR (>100 mL/min/1.73 m²) demonstrate better adaptive response and less risk of eGFR decline >30 mL/min/1.73 m² at one year 3.
Caveat: Newer studies comparing donors to equally healthy non‑donors (rather than the general population) suggest slightly increased long‑term risks of metabolic derangements, renal failure, and possibly mortality, emphasizing the importance of lifelong medical surveillance 10.